SiBone (NASDAQ:SIBN) Releases Earnings Results, Beats Estimates By $0.05 EPS

SiBone (NASDAQ:SIBN) released its quarterly earnings data on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05, FiscalAI reports. The firm had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%.

Here are the key takeaways from SiBone’s conference call:

• Third-quarter revenue rose 14.5% to $55.7 million, while U.S. procedure volume increased 19.5% and active physicians grew 16% to approximately 1,770. Management cited broad-based demand across surgeons, interventional spine physicians, and trauma procedures.
• The early alpha launch of iFuse Granite Onyx is generating demand ahead of the comparable Granite launch, including adoption by existing Granite users and new physicians. Onyx expands the company’s estimated addressable market to more than 650,000 procedures and approximately $5 billion.
• New spinal-fusion DRGs became effective October 1 and may increase hospital reimbursement by up to $50,000 for qualifying cases, supporting Granite adoption and potentially Onyx utilization. SI-BONE has also applied for an Onyx NTAP, which could take effect in October 2027 if approved.
• Profitability and cash generation improved, with adjusted EBITDA up 32.4% to $3.0 million, a 5.5% margin, and year-to-date operating cash flow of $4.4 million. The company lowered its expected 2026 operating-expense growth to 10.5% from 12% while reaffirming full-year revenue guidance of $231 million to $233 million.
• Average selling price declined because of a higher mix of lower-priced INTRA procedures in ASC and office settings and more two-implant Granite cases. Management expects modest gross-margin pressure in 2027 as it adds Onyx surgical capacity and launches additional products, although it continues to target long-term operating leverage.

SiBone Stock Down 4.8%

SIBN traded down $1.01 during trading on Monday, hitting $20.22. The stock had a trading volume of 1,371,299 shares, compared to its average volume of 616,959. The company has a market capitalization of $896.74 million, a PE ratio of -59.47 and a beta of 0.66. SiBone has a twelve month low of $11.48 and a twelve month high of $22.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The stock has a 50 day simple moving average of $19.41 and a two-hundred day simple moving average of $16.44.

Insider Transactions at SiBone

In other news, insider Anshul Maheshwari sold 11,636 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96. Following the transaction, the insider directly owned 223,284 shares of the company’s stock, valued at approximately $4,490,241.24. This represents a 4.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Dunn sold 20,000 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $18.47, for a total value of $369,400.00. Following the sale, the director owned 16,057 shares of the company’s stock, valued at approximately $296,572.79. This represents a 55.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 204,968 shares of company stock valued at $3,998,918. Corporate insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

SIBN has been the subject of a number of recent research reports. UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. TD Cowen increased their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, Truist Financial boosted their price target on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.